RxDoctor Payments Data

David Riker, MD

Internal Medicine · San Diego, CANPI 1164405528

Payments from drug & device makers

$87,135in general payments, 2019–2025

Across 53 payments — averaging $1644.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$40K
  • Cook Incorporated$28K
  • Novartis$16K
  • Cook Medical LLC$2K
  • Intuitive Surgical$1K
  • Breathe Technologies, Inc.$140
  • plus $151 from 2 others
$3,048in research payments, 2019–2025

Across 1 payment — averaging $3048.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$3K

What the payments were for

  • Speaking & faculty fees$28,44390%
  • Travel & lodging$1,8886%
  • Food & beverage$1,2404%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK8$40,028
Cook Incorporated9$28,492
Novartis3$15,537
Cook Medical LLC18$1,706
Intuitive Surgical4$1,082
Breathe Technologies, Inc.6$140
Pulmonx Corporation4$116
Boston Scientific1$34

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$87,135 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$710,381
Medicare patients
245
Services billed
5,923

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban20$7,181
Ipratropium-AlbuterolIpratropium/Albuterol Sulfate108$1,638
Levetiracetam11$1,196
Scopolamine11$958
Tolterodine Tartrate ErTolterodine Tartrate12$625
Potassium Chloride13$577
Modafinil12$491
Gabapentin19$348
Pregabalin19$300
Venlafaxine Hcl ErVenlafaxine Hcl13$243
Hydroxyzine Hcl13$199
Metformin Hcl14$183
Albuterol Sulfate18$173
Trazodone Hcl12$155
Atorvastatin Calcium13$153

Paid to pharmacies, not to this prescriber.

Other internal medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →